ENTA reports phase-2b RSV data—misses primary endpoint*—hits_various secondary endpoints: https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-positive-topline-results-its CC at 8:30am ET. *Time to mild symptoms in lower respiratory tract.